Aristides Capital LLC Has $889,000 Holdings in BioNTech SE Sponsored ADR $BNTX

Aristides Capital LLC lowered its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 62.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after selling 16,559 shares during the quarter. Aristides Capital LLC’s holdings in BioNTech were worth $889,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Larson Financial Group LLC boosted its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares in the last quarter. EFG International AG acquired a new position in shares of BioNTech in the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd raised its stake in shares of BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares during the period. Finally, Vestcor Inc bought a new position in shares of BioNTech during the 4th quarter worth about $153,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $130.00 target price on shares of BioNTech in a research report on Monday, April 27th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. Finally, Berenberg Bank dropped their target price on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average target price of $129.12.

BioNTech Stock Up 0.3%

Shares of NASDAQ:BNTX opened at $92.06 on Friday. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The company has a market capitalization of $23.28 billion, a PE ratio of -15.66 and a beta of 1.32. The company has a 50 day moving average price of $91.29 and a two-hundred day moving average price of $97.73.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, May 4th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.52) by $0.26. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The firm had revenue of $136.71 million for the quarter, compared to the consensus estimate of $207.42 million. During the same quarter last year, the business posted ($1.73) EPS. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. Analysts forecast that BioNTech SE Sponsored ADR will post -5.79 earnings per share for the current year.

BioNTech announced that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.